E/C/F/TDF + ATV + RTV + FTC/TDF + E/C/F/TDF Placebo + ATV Placebo + RTV Placebo + FTC/TDF Placebo + E/C/F/TAF

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Acquired Immunodeficiency Syndrome

Conditions

Acquired Immunodeficiency Syndrome, HIV Infections

Trial Timeline

Oct 24, 2012 → Sep 6, 2018

NCT ID

NCT01705574

About E/C/F/TDF + ATV + RTV + FTC/TDF + E/C/F/TDF Placebo + ATV Placebo + RTV Placebo + FTC/TDF Placebo + E/C/F/TAF

E/C/F/TDF + ATV + RTV + FTC/TDF + E/C/F/TDF Placebo + ATV Placebo + RTV Placebo + FTC/TDF Placebo + E/C/F/TAF is a phase 3 stage product being developed by Gilead Sciences for Acquired Immunodeficiency Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT01705574. Target conditions include Acquired Immunodeficiency Syndrome, HIV Infections.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01705574	Phase 3	Completed	Oct 24, 2012	Sep 6, 2018	Acquired Immunodeficiency Syndrome

Competing Products

20 competing products in Acquired Immunodeficiency Syndrome

See all competitors

Product	Company	Stage	Hype Score
ONO-5046Na + ONO-5046Na	Ono Pharmaceutical	Phase 2	52
epoetin alfa	Johnson & Johnson	Phase 2	52
epoetin alfa	Johnson & Johnson	Phase 2	52
HRS-8427 + Meropenem	Jiangsu Hengrui Medicine	Phase 2	52
Ticagrelor + Placebo	AstraZeneca	Phase 2	52
IMI/REL FDC + PIP/TAZ FDC + Linezolid	Merck	Phase 3	77
Raltegravir + Atazanavir	Merck	Pre-clinical	23
Emicizumab Injection	Roche	Phase 2	52
PI + RTV + FTC/TDF + Stribild	Gilead Sciences	Phase 3	76
E/C/F/TDF + COBI + ATV + DRV + NRTI	Gilead Sciences	Phase 3	76
COBI + DRV + NRTIs	Gilead Sciences	Phase 3	76
Stribild	Gilead Sciences	Phase 3	76
ATV + DRV + Cobicistat + BR + F/TAF + LPV/r + Third Unboosted Drug + Cobicistat TOS + F/TAF TOS	Gilead Sciences	Phase 2/3	64
D/C/F/TAF + DRV + COBI + FTC/TDF + D/C/F/TAF Placebo + DRV Placebo + COBI Placebo + FTC/TDF Placebo	Gilead Sciences	Phase 2	51
Lopinavir 400 mg/ritonavir 100 mg + Efavirenz	Gilead Sciences	Approved	84
E/C/F/TAF + E/C/F/TAF (Low Dose)	Gilead Sciences	Phase 2/3	64
NNRTI + FTC/TDF + Stribild	Gilead Sciences	Phase 3	76
E/C/F/TDF + E/C/F/TAF Placebo + E/C/F/TAF + E/C/F/TDF Placebo	Gilead Sciences	Phase 2	51
EVG + Background regimen	Gilead Sciences	Phase 2/3	64
EVG/COBI/FTC/TDF	Gilead Sciences	Phase 2/3	64

Other Products from Gilead Sciences

Ranolazine + PlaceboApproved

Truvada + Atazanavir + RitonavirApproved

Truvada + efavirenzApproved

B/F/TAF + Atripla + B/F/TAF Placebo + Atripla PlaceboApproved

TDF + Placebo Vaginal Gel + Vaginal TFV Gel + Placebo TabletsApproved